Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Standard Moderately Hypofractionated Radiotherapy vs. Ultra-hypofractionated Focal Lesion Ablative Microboost in Prostate Cancer, Hypo-FLAME 3.0

NCT05705921 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.

NCT NCT05705921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05705921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Standard Moderately Hypofractionated Radiotherapy vs. Ultra-hypofractionated Focal Lesion Ablative Microboost in Prostate Cancer, Hypo-FLAME 3.0
Lead sponsor
The Netherlands Cancer Institute
Phase
Not applicable
Overall status
Active, not recruiting
Start date
April 26, 2023
Completion date
January 1, 2032
Enrollment
484 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer